Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals results
119 filed, newest first. Page 3 of 3.
Oct 2008
27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 55971.93 lacs for quarter ending on 30-SEP-2008 against Rs. 37489.85 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 11736.01 lacs for the quarter ending on 30-SEP-2008 against Rs. 7512.64 lacs for the quarter ending on 30-SEP-2007.27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 41982.93 lacs for half year ending on 30-SEP-2008 against Rs. 54221.38 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 12372.24 lacs for the half year ending on 30-SEP-2008 against Rs. 11245.61 lacs for the half year ending on 30-SEP-2007.27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 22585.42 lacs for quarter ending on 30-SEP-2008 against Rs. 27926.68 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 6688.67 lacs for the quarter ending on 30-SEP-2008 against Rs. 6386.38 lacs for the quarter ending on 30-SEP-2007.7 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "Pursuant to the notice dated August 11, 2008, the shareholders of Glenmark Pharmaceuticals Ltd. have approved through postal ballot the Resolutions at the deemed Extraordinary General Meeting (EGM) held on October 06, 2008". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
28 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 19397.51 lacs for quarter ending on 30-JUN-2008 against Rs. 26294.7 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 5683.57 lacs for the quarter ending on 30-JUN-2008 against Rs. 4859.24 lacs for the quarter ending on 30-JUN-2007.28 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 46082.49 lacs for quarter ending on 30-JUN-2008 against Rs. 35135.66 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 11537.68 lacs for the quarter ending on 30-JUN-2008 against Rs. 5715.13 lacs for the quarter ending on 30-JUN-2007.
Apr 2008
28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 137269.08 lacs for year ending on 31-MAR-2008 against Rs. 80263.81 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 38902.38 lacs for the year ending on 31-MAR-2008 against Rs. 13480.44 lacs for the year ending on 31-MAR-2007.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 39689.78 lacs for quarter ending on 31-MAR-2008 against Rs. 27479.32 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 13014.09 lacs for the quarter ending on 31-MAR-2008 against Rs. 6256.32 lacs for the quarter ending on 31-MAR-2007.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 57269.58 lacs for quarter ending on 31-MAR-2008 against Rs. 33907.84 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 21896.32 lacs for the quarter ending on 31-MAR-2008 against Rs. 6325.83 lacs for the quarter ending on 31-MAR-2007.28 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 197834.2 lacs for year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 63125.97 lacs for the year ending on 31-MAR-2008.
Feb 2008
6 Feb · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Pursuant to the notice dated December 21, 2007, the shareholders of Glenmark Pharmaceuticals Ltd. have approved through postal ballot the Resolutions at the deemed Extraordinary General Meeting (EGM) held on February 05, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
21 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 43357.92 lacs for quarter ending on 31-DEC-2007 against Rs. 20186.56 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 14642.68 lacs for the quarter ending on 31-DEC-2007 against Rs. 3017.24 lacs for the quarter ending on 31-DEC-2006.21 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 67939.11 lacs for quarter ending on 31-DEC-2007 against Rs. 43802.53 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 28001.88 lacs for the quarter ending on 31-DEC-2007 against Rs. 18898.24 lacs for the quarter ending on 31-DEC-2006.
Oct 2007
31 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 72625.51 lacs for half year ending on 30-SEP-2007 against Rs. 42988.4 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 13227.75 lacs for the half year ending on 30-SEP-2007 against Rs. 5887.49 lacs for the half year ending on 30-SEP-2006.31 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 54221.38 lacs for half year ending on 30-SEP-2007 against Rs. 32597.93 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 11245.61 lacs for the half year ending on 30-SEP-2007 against Rs. 4206.88 lacs for the half year ending on 30-SEP-2006.31 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 27926.68 lacs for quarter ending on 30-SEP-2007 against Rs. 19634.98 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 6386.38 lacs for the quarter ending on 30-SEP-2007 against Rs. 3205.13 lacs for the quarter ending on 30-SEP-2006.
Jul 2007
30 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 35135.66 lacs for quarter ending on 30-JUN-2007 against Rs. 19155.33 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5715.13 lacs for the quarter ending on 30-JUN-2007 against Rs. 1867.37 lacs for the quarter ending on 30-JUN-2006.30 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 26294.7 lacs for quarter ending on 30-JUN-2007 against Rs. 13803.35 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4859.24 lacs for the quarter ending on 30-JUN-2007 against Rs. 1001.75 lacs for the quarter ending on 30-JUN-2006.28 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that pursuant to the notice dated June 12, 2007, the shareholders of Glenmark Pharmaceuticals Ltd have approved through postal ballot the Resolutions at the deemed Extraordinary General (EGM) held on July 27, 2007. The details of the results of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.